FDA approves Gamifant ® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease

Sobi's Gamifant (emapalumab-lzsg) has received FDA approval as the first-ever treatment for adult and pediatric patients with Macrophage Activation Syndrome (MAS) in Still's disease. This approval, based on pooled data from the pivotal EMERALD and NI-0501-06 studies demonstrating a 54% complete response rate at Week 8, expands Gamifant's existing indication for primary HLH and addresses a critical unmet medical need for a severe, life-threatening hyperinflammatory condition, bolstering Sobi's market position in rare disease therapeutics.

Analysis

Sobi has secured a significant regulatory milestone with the U.S. FDA's approval of Gamifant (emapalumab-lzsg) for a new indication, treating Macrophage Activation Syndrome (MAS) in adults and children with Still's disease. This approval positions Gamifant as the first-ever treatment for this severe and life-threatening condition, creating a new market for the drug. The approval is underpinned by compelling efficacy data from a pooled analysis of the pivotal EMERALD and NI-0501-06 studies, which showed that 54% of patients achieved a complete response at Week 8, and 82% reached clinical remission. This label expansion builds on Gamifant's existing approval for primary hemophagocytic lymphohistiocytosis (HLH), thereby increasing its total addressable market and reinforcing Sobi's strategic focus on high-value rare disease therapeutics. The reported safety profile, consistent with previous studies, suggests no new major concerns were identified, which should facilitate physician adoption.

Key Decisions for Investors

• This FDA approval is a material positive catalyst for Sobi, potentially driving near-term revenue upside from Gamifant and strengthening its orphan drug portfolio; investors may view this as a bullish signal.
• Focus should now shift to the commercial launch and market penetration for this new indication, as the speed of physician adoption and reimbursement access will be critical drivers of future earnings.
• The successful label expansion demonstrates management's ability to execute on its regulatory strategy and maximize the value of its assets, which may de-risk future pipeline developments in the rare disease space.